Cargando…
A Systems Pharmacology Perspective on the Clinical Development of Fatty Acid Amide Hydrolase Inhibitors for Pain
The level of the endocannabinoid anandamide is controlled by fatty acid amide hydrolase (FAAH). In 2011, PF-04457845, an irreversible inhibitor of FAAH, was progressed to phase II clinical trials for osteoarthritic pain. This article discusses a prospective, integrated systems pharmacology model eva...
Autores principales: | Benson, N, Metelkin, E, Demin, O, Li, G L, Nichols, D, van der Graaf, P H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910012/ https://www.ncbi.nlm.nih.gov/pubmed/24429592 http://dx.doi.org/10.1038/psp.2013.72 |
Ejemplares similares
-
Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10‐2474
por: Bonifácio, Maria‐João, et al.
Publicado: (2020) -
Benzylamides and piperazinoarylamides of ibuprofen as fatty acid amide hydrolase inhibitors
por: Deplano, Alessandro, et al.
Publicado: (2019) -
Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty
Acid Amide Hydrolase Inhibitors
por: Kodani, Sean D., et al.
Publicado: (2018) -
Involvement of Fatty Acid Amide Hydrolase and Fatty Acid Binding Protein 5 in the Uptake of Anandamide by Cell Lines with Different Levels of Fatty Acid Amide Hydrolase Expression: A Pharmacological Study
por: Björklund, Emmelie, et al.
Publicado: (2014) -
Effect of Fatty Acid Amide Hydrolase Inhibitor URB597 on Orofacial Pain Perception in Rats
por: Zubrzycki, Marek, et al.
Publicado: (2022)